|
1
|
Ornellas AA, Andrade DM, Ornellas P,
Wisnescky A and Schwindt AB: Prognostic factors in renal cell
carcinoma: Analysis of 227 patients treated at the Brazilian
National Cancer Institute. Int Braz J Urol. 38:185–194. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vera-Badillo FE, Conde E and Duran I:
Chromophobe renal cell carcinoma: A review of an uncommon entity.
Int J Urol. 19:894–900. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thoenes W, Störkel S and Rumpelt HJ: Human
chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl
Mol Pathol. 48:207–217. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peyromaure M, Misrai V, Thiounn N,
Vieillefond A, Zerbib M, Flam TA and Debré B: Chromophobe renal
cell carcinoma: Analysis of 61 cases. Cancer. 100:1406–1410. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yusenko MV, Zubakov D and Kovacs G: Gene
expression profiling of chromophobe renal cell carcinomas and renal
oncocytomas by Affymetrix GeneChip using pooled and individual
tumours. Int J Biol Sci. 5:517–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Speicher MR, Schoell B, du Manoir S,
Schröck E, Ried T, Cremer T, Störkel S, Kovacs A and Kovacs G:
Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in
chromophobe renal cell carcinomas revealed by comparative genomic
hybridization. Am J Pathol. 145:356–364. 1994.PubMed/NCBI
|
|
7
|
Yamazaki K, Sakamoto M, Ohta T, Kanai Y,
Ohki M and Hirohashi S: Overexpression of KIT in chromophobe renal
cell carcinoma. Oncogene. 22:847–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petit A, Castillo M, Santos M, Mellado B,
Alcover JB and Mallofré C: KIT expression in chromophobe renal cell
carcinoma: Comparative immunohistochemical analysis of KIT
expression in different renal cell neoplasms. Am J Surg Pathol.
28:676–678. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev
J, Matsuda D, Khoo SK, Sugimura J, Fujioka T, Furge KA, et al:
Genomic expression and single-nucleotide polymorphism profiling
discriminates chromophobe renal cell carcinoma and oncocytoma. BMC
Cancer. 10:1962010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weng WH, Ahlén J, Lui WO, Brosjö O, Pang
ST, Von Rosen A, Auer G, Larsson O and Larsson C: Gain of 17q in
malignant fibrous histiocytoma is associated with a longer
disease-free survival and a low risk of developing distant
metastasis. Br J Cancer. 79:720–726. 2003. View Article : Google Scholar
|
|
11
|
Ross JS, Fletcher JA, Bloom KJ, Linette
GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted
therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell
Proteomics. 3:379–398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shia J, Klimstra DS, Li AR, Qin J, Saltz
L, Teruya-Feldstein J, Akram M, Chung KY, Yao D, Paty PB, et al:
Epidermal growth factor receptor expression and gene amplification
in colorectal carcinoma: An immunohistochemical and chromogenic
in situ hybridization study. Mod Pathol. 18:1350–1356. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grob TJ, Kannengiesser I, Tsourlakis MC,
Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S,
Simon R, et al: Heterogeneity of ERBB2 amplification in
adenocarcinoma, squamous cell carcinoma and large cell
undifferentiated carcinoma of the lung. Mod Pathol. 25:1566–1573.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sergina NV and Moasser MM: The HER family
and cancer: Emerging molecular mechanisms and therapeutic targets.
Trends Mol Med. 13:527–534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ross JS and Fletcher JA: The HER-2/neu
oncogene in breast cancer: Prognostic factor, predictive factor,
and target for therapy. Stem Cells. 16:413–428. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nahta R and Esteva FJ: HER2 therapy:
Molecular mechanisms of trastuzumab resistance. Breast Cancer Res.
8:2152006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weidner U, Peter S, Strohmeyer T,
Hussnätter R, Ackermann R and Sies H: Inverse relationship of
epidermal growth factor receptor and HER2/neu gene expression in
human renal cell carcinoma. Cancer Res. 50:4504–4509.
1990.PubMed/NCBI
|
|
18
|
Latif Z, Watters AD, Bartlett JM,
Underwood MA and Aitchison M: Gene amplification and overexpression
of HER2 in renal cell carcinoma. BJU Int. 89:5–9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thomasson M, Hedman H, Junttila TT,
Elenius K, Ljungberg B and Henriksson R: ErbB4 is downregulated in
renal cell carcinoma - a quantitative RT-PCR and
immunohistochemical analysis of the epidermal growth factor
receptor family. Acta Oncol. 43:453–459. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seliger B, Rongcun Y, Atkins D, Hammers S,
Huber C, Störkel S and Kiessling R: HER-2/neu is expressed in human
renal cell carcinoma at heterogeneous levels independently of tumor
grading and staging and can be recognized by HLA-A2.1-restricted
cytotoxic T lymphocytes. Int J Cancer. 87:349–359. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brunelli M, Delahunt B, Gobbo S, Tardanico
R, Eccher A, Bersani S, Cossu-Rocca P, Parolini C, Balzarini P,
Menestrina F, et al: Diagnostic usefulness of fluorescent
cytogenetics in differentiating chromophobe renal cell carcinoma
from renal oncocytoma: A validation study combining metaphase and
interphase analyses. Am J Clin Pathol. 133:116–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iqbal MA, Akhtar M, Ulmer C, Al-Dayel F
and Paterson MC: FISH analysis in chromophobe renal-cell carcinoma.
Diagn Cytopathol. 22:3–6. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ho-Pun-Cheung A, Assenat E,
Bascoul-Mollevi C, Bibeau F, Boissière-Michot F, Cellier D, Azria
D, Rouanet P, Senesse P, Ychou M and Lopez-Crapez E: EGFR and HER3
mRNA expression levels predict distant metastases in locally
advanced rectal cancer. Int J Cancer. 128:2938–2946. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao M, Shuin T, Misaki H and Kubota Y:
Enhanced expression of c-myc and epidermal growth factor receptor
(C-erbB-1) genes in primary human renal cancer. Cancer Res.
48:6753–6757. 1988.PubMed/NCBI
|
|
25
|
Moch H, Sauter G, Gasser TC, Bubendorf L,
Richter J, Presti JC Jr, Waldman FM and Mihatsch MJ: EGF-r gene
copy number changes in renal cell carcinoma detected by
fluorescence in situ hybridization. J Pathol. 184:424–429.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takikita M, Xie R, Chung JY, Cho H, Ylaya
K, Hong SM, Moskaluk CA and Hewitt SM: Membranous expression of
Her3 is associated with a decreased survival in head and neck
squamous cell carcinoma. J Transl Med. 9:1262011. View Article : Google Scholar : PubMed/NCBI
|
